Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non–small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study

Introduction: Patients with advanced non-small cell lung cancer (NSCLC) who progress after chemotherapy and immune checkpoint inhibitors (ICIs) need effective second-line treatments. The combination of nintedanib and docetaxel has shown promise, particularly post-ICI progression. This study evaluate...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Natalia Fernández Núñez, Martín Lázaro Quintela, Jorge García González, Francisco Javier Afonso Afonso, María Carmen Areses Manrique, Cristina Azpitarte Raposeiras, Joaquin Mosquera Martinez, Lucia Santomé Couto
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2025-01-01
Rangatū:	Cancer Treatment and Research Communications
Ngā marau:	Non–small cell lung cancer Nintedanib Docetaxel
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S2468294225000991
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!